About Alkem Laboratories Limited
Data last updated: 17 December 2025
Alkem Laboratories Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 08 August 1973, the company has been in operation for over 53 years.
Registered with ROC Mumbai under CIN L00305MH1973PLC174201. Listed on BSE: 539523 and NSE: ALKEM.
Capital: an authorised share capital of ₹50 Cr and a paid-up capital of ₹23.91 Cr. Formerly known as Alkem Laboratories Private Limited. It is led by directors including Rajeev Kher and Diwakar Gupta.
Last AGM: 25 August 2025. Financial statements filed for year ended 31 March 2025. Office: Alkem House Senapati Bapat Marg Lower Parel, Mumbai, Maharashtra, India – 400013.
As per the financials filed for FY 2025, the company reported a revenue of ₹13,458 Cr, a growth of 4% compared to the previous year.
The company has a workforce of approximately 18,498 employees as per the latest available data. Its group structure includes 5 subsidiaries.
The company is associated with 4 brands - Connect2clinic, Alkem Laboratories Ltd, Enzene Biosciences, Alkem Laboratories. As per MCA filings, the company has open charges of ₹1,085.77 Cr and satisfied charges of ₹4,919.56 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website alkemlabs.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressAlkem House Senapati Bapat Marg Lower Parel, Mumbai, Maharashtra, India – 400013
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Alkem Laboratories Limited
Alkem Laboratories Limited has one previous CIN (Corporate Identification Number): U00305MH1973PLC174201. The current CIN is L00305MH1973PLC174201, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L00305MH1973PLC174201 | Current |
| U00305MH1973PLC174201 | Previous |
Associated Brands with Alkem Laboratories Limited
Alkem Laboratories Limited operates multiple associated brands including Connect2Clinic, Alkem Laboratories Ltd, and Enzene Biosciences. These brands represent Alkem Laboratories Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Provides comprehensive teleconsultation solutions for patients and healthcare professionals. | connect2clinic.com | |
| Company specializing in development of Biosimilars | enzene.com | |
| Pharmaceutical generics, formulations, and nutraceuticals are manufactured for therapeutic segments. | alkemlabs.com | |
| Production of FOS and related dietary fibers for food and health applications in India. | foshealth.in |
Competitors & Alternatives of Alkem Laboratories Limited
Brands and companies operating in the same space as Alkem Laboratories Limited include Mosaic Wellness, DocsApp, MyHealthcare and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Mosaic Wellness
|
Provider of digital health coaching platforms for men, women, and parents | Mumbai, India, India | 2019 |
DocsApp
|
Chat-based mobile app for doctor teleconsultations is provided to patients. | Bengaluru, India, India | 2012 |
MyHealthcare
|
Provider of comprehensive digital healthcare ecosystem | Gurugram, India, India | 2017 |
Hybio Pharmaceutical
|
Polypeptide drugs and APIs are developed and manufactured. | Shenzhen, China, China | 1998 |
MediAngels
|
Online telemedicine platform for specialist consultation and second opinion | Mumbai, India, India | 2009 |
Bajaj Finserv Health
|
Provides online doctor consultations, lab bookings, and medicine ordering services. | Pune, India, India | 2019 |
PolyPeptide
|
Proprietary, GMP-grade, and non-GMP peptides are manufactured by PolyPeptide Labs. | Baar, Switzerland, Switzerland | 1952 |
AmbioPharm
|
CDMO and analytical services for peptide development are provided. | North Augusta, United States, United States | 2006 |
Mojocare
|
Personalized wellness solutions are delivered via a digital healthcare platform. | Bengaluru, India, India | 2020 |
vivitide
|
Drug development services for neoantigen peptides and antibodies are provided. | Gardner, United States, United States | 1983 |
Business Activity of Alkem Laboratories Limited
Alkem Laboratories Limited is engaged in principal business activities including manufacturing and trade, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products, wholesale trading. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Alkem Laboratories Limited
Alkem Laboratories Limited is audited by Deloitte Haskins and Sells LLP (ICAI peer reviewed, certificate valid till 2027-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Deloitte Haskins and Sells LLP (ICAI peer reviewed, certificate valid till 2027-07-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Alkem Laboratories Limited
Alkem Laboratories Limited is currently managed by 15 directors, with 31 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Rajeev Kher
Also directs:
Star Health And Allied Insurance Company Limited, Okiyo Terraces Private Limited, Airtel Payments Bank Limited and 1 more
|
Director | 09 Aug 2024 | 1 Years 11 Months | Current |
| Diwakar Gupta | Director | 13 Jul 2025 | 0 Years 11 Months | Current |
| Madhurima Singh | Whole-Time Director | 20 Dec 2021 | 4 Years 6 Months | Current |
| Sarvesh Singh | Whole-Time Director | 11 Nov 2019 | 6 Years 7 Months | Current |
| Basudeo Narayan Singh | Whole-Time Director | 08 Aug 1973 | 52 Years 11 Months | Current |
| Mritunjay Kumar Singh | Whole-Time Director | 11 Feb 2008 | 18 Years 4 Months | Current |
Financials of Alkem Laboratories Limited FY 2026 filings available
Alkem Laboratories Limited reported revenue of ₹14,712 Cr (up 13.48% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹14,712 Cr | ₹12,965 Cr | ₹12,668 Cr | ₹11,599 Cr | ₹10,634 Cr | ₹8,344.36 Cr |
| Other Income | ₹583.35 Cr | ₹493.74 Cr | ₹310.84 Cr | ₹216.08 Cr | ₹162.65 Cr | ₹104.22 Cr |
| Total Income | ₹15,296 Cr | ₹13,458 Cr | ₹12,978 Cr | ₹11,815 Cr | ₹10,797 Cr | ₹8,448.58 Cr |
| Cost of Materials Consumed | ₹3,565.39 Cr | ₹3,440.37 Cr | ₹3,294.59 Cr | ₹3,056.92 Cr | ₹3,226.06 Cr | ₹2,131.83 Cr |
| Purchases of Stock-in-Trade | ₹1,694.5 Cr | ₹1,514.02 Cr | ₹1,628.87 Cr | ₹1,387.55 Cr | ₹1,489.71 Cr | ₹1,443.06 Cr |
| Changes in Inventories | -₹167.12 Cr | -₹190.13 Cr | ₹14.12 Cr | ₹462.37 Cr | -₹535.48 Cr | -₹229.95 Cr |
| Employee Benefit Expense | ₹2,837.11 Cr | ₹2,453.92 Cr | ₹2,201.01 Cr | ₹2,131.35 Cr | ₹1,962.71 Cr | ₹1,505.49 Cr |
| Finance Costs | ₹160.78 Cr | ₹121.7 Cr | ₹112.41 Cr | ₹107.36 Cr | ₹52.37 Cr | ₹65.06 Cr |
| Depreciation & Amortisation | ₹382.06 Cr | ₹357.16 Cr | ₹299.3 Cr | ₹310.42 Cr | ₹303.96 Cr | ₹252.76 Cr |
| Other Expenses | ₹3,777.18 Cr | ₹3,234.19 Cr | ₹3,283.5 Cr | ₹2,951.62 Cr | ₹2,438.27 Cr | ₹2,020.54 Cr |
| Total Expenses | ₹12,250 Cr | ₹10,931 Cr | ₹10,834 Cr | ₹10,408 Cr | ₹8,937.6 Cr | ₹7,188.79 Cr |
| Profit Before Exceptional Items & Tax | ₹3,045.72 Cr | ₹2,527.03 Cr | ₹2,144.62 Cr | ₹1,407.75 Cr | ₹1,859.24 Cr | ₹1,259.79 Cr |
| Exceptional Items | -₹174.83 Cr | ₹0 | -₹121.49 Cr | -₹102.98 Cr | -₹14.96 Cr | ₹0 |
| Profit Before Tax | ₹2,870.89 Cr | ₹2,527.03 Cr | ₹2,023.13 Cr | ₹1,304.77 Cr | ₹1,844.28 Cr | ₹1,259.79 Cr |
| Total Tax Expense | ₹517.76 Cr | ₹311.03 Cr | ₹211.67 Cr | ₹297.96 Cr | ₹163.96 Cr | ₹110.48 Cr |
| Net Profit | ₹2,351.16 Cr | ₹2,215.38 Cr | ₹1,811.46 Cr | ₹1,006.81 Cr | ₹1,680.32 Cr | ₹1,149.31 Cr |
| attributable to Owners | ₹2,301.8 Cr | ₹2,165.48 Cr | ₹1,795.77 Cr | ₹984.17 Cr | ₹1,645.62 Cr | ₹1,127.07 Cr |
| attributable to NCI | ₹49.36 Cr | ₹49.9 Cr | ₹15.69 Cr | ₹22.64 Cr | ₹34.7 Cr | ₹22.24 Cr |
| Other Comprehensive Income | ₹183.79 Cr | ₹19.72 Cr | ₹20.04 Cr | ₹114.9 Cr | ₹34.14 Cr | ₹26.86 Cr |
| Total Comprehensive Income | ₹2,534.95 Cr | ₹2,235.1 Cr | ₹1,831.5 Cr | ₹1,121.71 Cr | ₹1,714.46 Cr | ₹1,176.17 Cr |
| EBITDA (computed) | ₹3,588.56 Cr | ₹3,005.89 Cr | ₹2,556.33 Cr | ₹1,825.53 Cr | ₹2,215.57 Cr | ₹1,577.61 Cr |
| Basic EPS | ₹192.51 | ₹181.11 | ₹150.19 | ₹82.31 | ₹137.63 | ₹94.26 |
| Diluted EPS | ₹192.51 | ₹181.11 | ₹150.19 | ₹82.31 | ₹137.63 | ₹94.26 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹20,873 Cr | ₹17,691 Cr | ₹15,575 Cr | ₹13,757 Cr |
| Non-current Assets | ₹8,662.45 Cr | ₹6,745.28 Cr | ₹5,163.32 Cr | ₹5,026.97 Cr |
| Current Assets | ₹12,211 Cr | ₹10,811 Cr | ₹10,412 Cr | ₹8,606.42 Cr |
| Property, Plant & Equipment | ₹2,694.97 Cr | ₹2,063.93 Cr | ₹2,161.46 Cr | ₹2,065.4 Cr |
| Inventories | ₹3,333.22 Cr | ₹2,922.41 Cr | ₹2,661.18 Cr | ₹2,607.53 Cr |
| Trade Receivables | ₹2,979.11 Cr | ₹2,466.25 Cr | ₹2,252.81 Cr | ₹2,132.18 Cr |
| Cash & Equivalents | ₹247.91 Cr | ₹304.14 Cr | ₹455.07 Cr | ₹273.8 Cr |
| Equity (Net Worth) | ₹14,349 Cr | ₹12,434 Cr | ₹10,714 Cr | ₹9,435 Cr |
| Equity Share Capital | ₹23.91 Cr | ₹23.91 Cr | ₹23.91 Cr | ₹23.91 Cr |
| Borrowings (Non-current) | ₹492.45 Cr | ₹310.91 Cr | ₹40 Cr | ₹70.33 Cr |
| Borrowings (Current) | ₹1,131.05 Cr | ₹751.88 Cr | ₹1,173.97 Cr | ₹1,326.35 Cr |
| Total Debt (computed) | ₹1,623.5 Cr | ₹1,062.79 Cr | ₹1,213.97 Cr | ₹1,396.68 Cr |
| Current Liabilities | ₹4,782.7 Cr | ₹3,958.69 Cr | ₹3,994.55 Cr | ₹3,707.15 Cr |
| Total Liabilities | ₹6,524.04 Cr | ₹5,257.47 Cr | ₹4,860.5 Cr | ₹4,321.65 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹1,963.03 Cr | ₹1,912.84 Cr | ₹1,948.08 Cr | ₹1,682.5 Cr | ₹1,111.02 Cr |
| Investing Cash Flow | -₹1,667.21 Cr | -₹1,298.76 Cr | -₹1,008.51 Cr | ₹112.84 Cr | -₹1,435.13 Cr |
| Financing Cash Flow | -₹503.4 Cr | -₹810.99 Cr | -₹1,145.01 Cr | -₹1,760.82 Cr | ₹379.57 Cr |
| Capital Expenditure | ₹617.26 Cr | ₹675.62 Cr | ₹259.29 Cr | ₹232.91 Cr | ₹338.88 Cr |
| Free Cash Flow (computed) | ₹1,345.77 Cr | ₹1,237.22 Cr | ₹1,688.79 Cr | ₹1,449.59 Cr | ₹772.14 Cr |
| Dividends Paid | ₹613.7 Cr | ₹504.62 Cr | ₹540.49 Cr | ₹529.52 Cr | ₹421.91 Cr |
| Net Change in Cash | -₹222.04 Cr | -₹186.4 Cr | -₹207.49 Cr | ₹41.62 Cr | ₹57.96 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹3,603.32 Cr | ₹3,736.82 Cr | ₹4,000.99 Cr | ₹3,371.14 Cr | ₹3,143.75 Cr | ₹3,374.28 Cr | ₹3,414.67 Cr | ₹3,031.82 Cr | ₹2,935.82 Cr | ₹3,323.87 Cr | ₹3,440.17 Cr | ₹2,967.72 Cr |
| Other Income | ₹200.07 Cr | ₹143.1 Cr | ₹103.69 Cr | ₹136.49 Cr | ₹145.96 Cr | ₹92.99 Cr | ₹134.48 Cr | ₹120.31 Cr | ₹88.17 Cr | ₹93.64 Cr | ₹63.19 Cr | ₹65.84 Cr |
| Total Income | ₹3,803.39 Cr | ₹3,879.92 Cr | ₹4,104.68 Cr | ₹3,507.63 Cr | ₹3,289.71 Cr | ₹3,467.27 Cr | ₹3,549.15 Cr | ₹3,152.13 Cr | ₹3,023.99 Cr | ₹3,417.51 Cr | ₹3,503.36 Cr | ₹3,033.56 Cr |
| Cost of Materials Consumed | ₹894.94 Cr | ₹937.77 Cr | ₹905.57 Cr | ₹827.11 Cr | ₹777.03 Cr | ₹924.01 Cr | ₹902.17 Cr | ₹837.16 Cr | ₹798.76 Cr | ₹838.54 Cr | ₹824.71 Cr | ₹832.58 Cr |
| Purchases of Stock-in-Trade | ₹497.77 Cr | ₹327.96 Cr | ₹471.57 Cr | ₹397.2 Cr | ₹379.96 Cr | ₹397.48 Cr | ₹353.92 Cr | ₹382.66 Cr | ₹380.7 Cr | ₹460.81 Cr | ₹431.89 Cr | ₹355.47 Cr |
| Changes in Inventories | -₹144.84 Cr | ₹6.98 Cr | ₹23.89 Cr | -₹53.15 Cr | ₹122.29 Cr | -₹117.16 Cr | -₹51.39 Cr | -₹143.87 Cr | -₹72.06 Cr | ₹5.19 Cr | ₹70.47 Cr | ₹10.52 Cr |
| Employee Benefit Expense | ₹712.1 Cr | ₹721.51 Cr | ₹710.25 Cr | ₹693.25 Cr | ₹616.35 Cr | ₹624.81 Cr | ₹610.49 Cr | ₹602.27 Cr | ₹505.83 Cr | ₹572.15 Cr | ₹555.38 Cr | ₹567.65 Cr |
| Finance Costs | ₹53.88 Cr | ₹42.1 Cr | ₹35.02 Cr | ₹29.78 Cr | ₹28.42 Cr | ₹36.03 Cr | ₹28.14 Cr | ₹29.11 Cr | ₹26.86 Cr | ₹25.46 Cr | ₹30.32 Cr | ₹29.77 Cr |
| Depreciation & Amortisation | ₹105.76 Cr | ₹95.01 Cr | ₹93.61 Cr | ₹87.68 Cr | ₹112.49 Cr | ₹85.28 Cr | ₹78.91 Cr | ₹80.48 Cr | ₹83.43 Cr | ₹69.56 Cr | ₹73.9 Cr | ₹72.41 Cr |
| Other Expenses | ₹1,125.96 Cr | ₹914.6 Cr | ₹968.94 Cr | ₹767.68 Cr | ₹856.83 Cr | ₹785.75 Cr | ₹846.65 Cr | ₹744.96 Cr | ₹920.61 Cr | ₹739.59 Cr | ₹810.99 Cr | ₹812.31 Cr |
| Total Expenses | ₹3,245.57 Cr | ₹3,045.93 Cr | ₹3,208.85 Cr | ₹2,749.55 Cr | ₹2,893.37 Cr | ₹2,736.2 Cr | ₹2,768.89 Cr | ₹2,532.77 Cr | ₹2,644.13 Cr | ₹2,711.3 Cr | ₹2,797.66 Cr | ₹2,680.71 Cr |
| Profit Before Exceptional Items & Tax | ₹557.82 Cr | ₹833.99 Cr | ₹895.83 Cr | ₹758.08 Cr | ₹396.34 Cr | ₹731.07 Cr | ₹780.26 Cr | ₹619.36 Cr | ₹379.86 Cr | ₹706.21 Cr | ₹705.7 Cr | ₹352.85 Cr |
| Exceptional Items | -₹134.97 Cr | -₹52.79 Cr | ₹0 | ₹12.93 Cr | ₹0 | ₹0 | ₹0 | ₹0 | -₹12.52 Cr | -₹51.31 Cr | -₹57.66 Cr | ₹0 |
| Profit Before Tax | ₹422.85 Cr | ₹781.2 Cr | ₹895.83 Cr | ₹771.01 Cr | ₹396.34 Cr | ₹731.07 Cr | ₹780.26 Cr | ₹619.36 Cr | ₹367.34 Cr | ₹654.9 Cr | ₹648.04 Cr | ₹352.85 Cr |
| Total Tax Expense | ₹171.17 Cr | ₹127.67 Cr | ₹116.23 Cr | ₹102.69 Cr | ₹73.33 Cr | ₹90.28 Cr | ₹78.3 Cr | ₹69.12 Cr | ₹62.86 Cr | ₹50.62 Cr | ₹33.15 Cr | ₹65.04 Cr |
| Net Profit | ₹251.11 Cr | ₹653.03 Cr | ₹779.11 Cr | ₹667.91 Cr | ₹322.39 Cr | ₹640.79 Cr | ₹701.96 Cr | ₹550.24 Cr | ₹304.48 Cr | ₹604.28 Cr | ₹614.89 Cr | ₹287.81 Cr |
| attributable to Owners | ₹236.46 Cr | ₹636.02 Cr | ₹765.06 Cr | ₹664.26 Cr | ₹305.86 Cr | ₹625.82 Cr | ₹688.64 Cr | ₹545.16 Cr | ₹293.56 Cr | ₹594.96 Cr | ₹620.52 Cr | ₹286.73 Cr |
| attributable to NCI | ₹14.65 Cr | ₹17.01 Cr | ₹14.05 Cr | ₹3.65 Cr | ₹16.53 Cr | ₹14.97 Cr | ₹13.32 Cr | ₹5.08 Cr | ₹10.92 Cr | ₹9.32 Cr | -₹5.63 Cr | ₹1.08 Cr |
| Other Comprehensive Income | ₹115.27 Cr | ₹23.57 Cr | ₹42.87 Cr | ₹2.08 Cr | -₹2.59 Cr | ₹12.1 Cr | ₹6.1 Cr | ₹4.11 Cr | -₹7.65 Cr | ₹5.48 Cr | ₹10.99 Cr | ₹11.22 Cr |
| Total Comprehensive Income | ₹366.38 Cr | ₹676.6 Cr | ₹821.98 Cr | ₹669.99 Cr | ₹319.8 Cr | ₹652.89 Cr | ₹708.06 Cr | ₹554.35 Cr | ₹296.83 Cr | ₹609.76 Cr | ₹625.88 Cr | ₹299.03 Cr |
| EBITDA (computed) | ₹717.46 Cr | ₹971.1 Cr | ₹1,024.46 Cr | ₹875.54 Cr | ₹537.25 Cr | ₹852.38 Cr | ₹887.31 Cr | ₹728.95 Cr | ₹490.15 Cr | ₹801.23 Cr | ₹809.92 Cr | ₹455.03 Cr |
| Basic EPS | ₹19.77 | ₹53.19 | ₹63.99 | ₹55.56 | ₹25.57 | ₹52.34 | ₹57.60 | ₹45.60 | ₹24.55 | ₹49.76 | ₹51.90 | ₹23.98 |
| Diluted EPS | ₹19.77 | ₹53.19 | ₹63.99 | ₹55.56 | ₹25.57 | ₹52.34 | ₹57.60 | ₹45.60 | ₹24.55 | ₹49.76 | ₹51.90 | ₹23.98 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹9,663.91 Cr | ₹8,813.44 Cr | ₹9,747.72 Cr | ₹9,054.55 Cr | ₹8,829.81 Cr | ₹7,219.68 Cr | ₹6,677.08 Cr |
| Other Income | ₹555.17 Cr | ₹507.06 Cr | ₹305.99 Cr | ₹266.29 Cr | ₹199.89 Cr | ₹190.01 Cr | ₹95.98 Cr |
| Total Income | ₹10,219 Cr | ₹9,320.5 Cr | ₹10,054 Cr | ₹9,320.84 Cr | ₹9,029.7 Cr | ₹7,409.69 Cr | ₹6,773.06 Cr |
| Cost of Materials Consumed | ₹2,429.33 Cr | ₹2,395.92 Cr | ₹2,749.93 Cr | ₹2,629.78 Cr | ₹2,849.75 Cr | ₹2,046.52 Cr | ₹1,799.87 Cr |
| Purchases of Stock-in-Trade | ₹426.95 Cr | ₹389.61 Cr | ₹1,128.7 Cr | ₹943.13 Cr | ₹1,077.04 Cr | ₹919.79 Cr | ₹784.38 Cr |
| Changes in Inventories | -₹45.67 Cr | ₹56.61 Cr | -₹71.31 Cr | ₹257.73 Cr | -₹360.9 Cr | -₹301.29 Cr | -₹33.69 Cr |
| Employee Benefit Expense | ₹1,883.03 Cr | ₹1,630.96 Cr | ₹1,560.28 Cr | ₹1,516.22 Cr | ₹1,434.49 Cr | ₹1,158.72 Cr | ₹1,066.76 Cr |
| Finance Costs | ₹57.29 Cr | ₹76.11 Cr | ₹81.91 Cr | ₹86.4 Cr | ₹37.9 Cr | ₹42.93 Cr | ₹38.71 Cr |
| Depreciation & Amortisation | ₹256.56 Cr | ₹283.61 Cr | ₹244.35 Cr | ₹229.85 Cr | ₹218.98 Cr | ₹198.93 Cr | ₹186.84 Cr |
| Other Expenses | ₹2,545.88 Cr | ₹2,184.14 Cr | ₹2,414.99 Cr | ₹2,330.74 Cr | ₹2,019.07 Cr | ₹1,447.01 Cr | ₹1,592.11 Cr |
| Total Expenses | ₹7,553.37 Cr | ₹7,016.96 Cr | ₹8,108.85 Cr | ₹7,993.85 Cr | ₹7,276.33 Cr | ₹5,512.61 Cr | ₹5,434.98 Cr |
| Profit Before Exceptional Items & Tax | ₹2,665.71 Cr | ₹2,303.54 Cr | ₹1,944.86 Cr | ₹1,326.99 Cr | ₹1,753.37 Cr | ₹1,897.08 Cr | ₹1,338.08 Cr |
| Exceptional Items | -₹143.09 Cr | ₹0 | -₹63.83 Cr | ₹0 | ₹0 | -₹12.78 Cr | ₹0 |
| Profit Before Tax | ₹2,522.62 Cr | ₹2,303.54 Cr | ₹1,881.03 Cr | ₹1,326.99 Cr | ₹1,753.37 Cr | ₹1,884.3 Cr | ₹1,338.08 Cr |
| Total Tax Expense | ₹337.5 Cr | ₹213.82 Cr | ₹133.88 Cr | ₹192.52 Cr | ₹212.12 Cr | ₹199.22 Cr | ₹73.66 Cr |
| Net Profit | ₹2,282.09 Cr | ₹2,280.89 Cr | ₹1,747.15 Cr | ₹1,134.47 Cr | ₹1,541.25 Cr | ₹1,685.08 Cr | ₹1,264.42 Cr |
| Other Comprehensive Income | ₹4.62 Cr | -₹11.5 Cr | -₹4.35 Cr | -₹2.19 Cr | -₹4.86 Cr | -₹4.99 Cr | -₹17.28 Cr |
| Total Comprehensive Income | ₹2,286.71 Cr | ₹2,269.39 Cr | ₹1,742.8 Cr | ₹1,132.28 Cr | ₹1,536.39 Cr | ₹1,680.09 Cr | ₹1,247.14 Cr |
| EBITDA (computed) | ₹2,979.56 Cr | ₹2,663.26 Cr | ₹2,271.12 Cr | ₹1,643.24 Cr | ₹2,010.25 Cr | ₹2,138.94 Cr | ₹1,563.63 Cr |
| Basic EPS | ₹182.76 | ₹174.78 | ₹146.13 | ₹94.88 | ₹128.90 | ₹140.93 | ₹105.75 |
| Diluted EPS | ₹182.76 | ₹174.78 | ₹146.13 | ₹94.88 | ₹128.90 | ₹140.93 | ₹105.75 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹17,261 Cr | ₹15,596 Cr | ₹14,038 Cr | ₹12,731 Cr |
| Non-current Assets | ₹9,431.01 Cr | ₹7,247.53 Cr | ₹5,997.72 Cr | ₹5,959.01 Cr |
| Current Assets | ₹7,830.12 Cr | ₹7,354 Cr | ₹8,040.08 Cr | ₹6,772.21 Cr |
| Property, Plant & Equipment | ₹1,422.39 Cr | ₹1,482.37 Cr | ₹1,659.67 Cr | ₹1,672.52 Cr |
| Inventories | ₹1,631.76 Cr | ₹1,522.9 Cr | ₹1,849.56 Cr | ₹1,724.66 Cr |
| Trade Receivables | ₹1,567.24 Cr | ₹1,559.84 Cr | ₹1,753.64 Cr | ₹1,768.34 Cr |
| Cash & Equivalents | ₹65.45 Cr | ₹74.92 Cr | ₹38.95 Cr | ₹5.01 Cr |
| Equity (Net Worth) | ₹13,999 Cr | ₹12,322 Cr | ₹10,555 Cr | ₹9,349.85 Cr |
| Equity Share Capital | ₹23.91 Cr | ₹23.91 Cr | ₹23.91 Cr | ₹23.91 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹45.06 Cr |
| Borrowings (Current) | ₹539.24 Cr | ₹371.24 Cr | ₹957.23 Cr | ₹1,136.63 Cr |
| Total Debt (computed) | ₹539.24 Cr | ₹371.24 Cr | ₹957.23 Cr | ₹1,181.69 Cr |
| Current Liabilities | ₹2,746.81 Cr | ₹2,543.44 Cr | ₹3,106.4 Cr | ₹3,044.83 Cr |
| Total Liabilities | ₹3,262.37 Cr | ₹3,273.77 Cr | ₹3,483.19 Cr | ₹3,381.37 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹1,969.12 Cr | ₹2,189.41 Cr | ₹1,686.56 Cr | ₹1,437.42 Cr | ₹1,299.34 Cr |
| Investing Cash Flow | -₹1,461.25 Cr | -₹1,007.41 Cr | -₹865.61 Cr | ₹197.04 Cr | -₹1,669.34 Cr |
| Financing Cash Flow | -₹672.82 Cr | -₹1,036.89 Cr | -₹959.04 Cr | -₹1,711.27 Cr | ₹436.59 Cr |
| Capital Expenditure | ₹277.27 Cr | ₹226.2 Cr | ₹106.68 Cr | ₹141.78 Cr | ₹244.87 Cr |
| Free Cash Flow (computed) | ₹1,691.85 Cr | ₹1,963.21 Cr | ₹1,579.88 Cr | ₹1,295.64 Cr | ₹1,054.46 Cr |
| Dividends Paid | ₹609.78 Cr | ₹502.17 Cr | ₹538.04 Cr | ₹526.09 Cr | ₹418.48 Cr |
| Net Change in Cash | -₹164.95 Cr | ₹145.11 Cr | -₹138.09 Cr | -₹76.81 Cr | ₹66.59 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹2,258.44 Cr | ₹2,491.27 Cr | ₹2,542.03 Cr | ₹2,372.17 Cr | ₹2,044.94 Cr | ₹2,286.83 Cr | ₹2,871.97 Cr | ₹2,500.1 Cr | ₹2,365.37 Cr | ₹2,494.59 Cr | ₹2,634.59 Cr | ₹2,253.17 Cr |
| Other Income | ₹205.69 Cr | ₹131.53 Cr | ₹101.37 Cr | ₹116.58 Cr | ₹111.59 Cr | ₹169.18 Cr | ₹120.19 Cr | ₹106.1 Cr | ₹83.79 Cr | ₹95.66 Cr | ₹61.84 Cr | ₹64.7 Cr |
| Total Income | ₹2,464.13 Cr | ₹2,622.8 Cr | ₹2,643.4 Cr | ₹2,488.75 Cr | ₹2,156.53 Cr | ₹2,456.01 Cr | ₹2,992.16 Cr | ₹2,606.2 Cr | ₹2,449.16 Cr | ₹2,590.25 Cr | ₹2,696.43 Cr | ₹2,317.87 Cr |
| Cost of Materials Consumed | ₹658.86 Cr | ₹587.51 Cr | ₹567.63 Cr | ₹615.33 Cr | ₹451.41 Cr | ₹693.13 Cr | ₹732.29 Cr | ₹761.23 Cr | ₹652.71 Cr | ₹700.73 Cr | ₹707.12 Cr | ₹689.37 Cr |
| Purchases of Stock-in-Trade | ₹107.5 Cr | ₹113.1 Cr | ₹122.84 Cr | ₹83.51 Cr | ₹85.24 Cr | ₹120.9 Cr | ₹315.4 Cr | ₹207.36 Cr | ₹269.96 Cr | ₹331.18 Cr | ₹282.39 Cr | ₹245.17 Cr |
| Changes in Inventories | -₹66.67 Cr | ₹15.67 Cr | -₹2.6 Cr | ₹7.93 Cr | ₹187.14 Cr | -₹88.15 Cr | ₹39.37 Cr | -₹85.66 Cr | ₹8.67 Cr | -₹27.41 Cr | ₹10.66 Cr | -₹63.23 Cr |
| Employee Benefit Expense | ₹466.86 Cr | ₹485.58 Cr | ₹460.85 Cr | ₹469.74 Cr | ₹401.63 Cr | ₹418.48 Cr | ₹429.76 Cr | ₹425.9 Cr | ₹343.41 Cr | ₹407.63 Cr | ₹395.18 Cr | ₹414.06 Cr |
| Finance Costs | ₹16.24 Cr | ₹15.51 Cr | ₹12.75 Cr | ₹12.79 Cr | ₹16.91 Cr | ₹21 Cr | ₹17.57 Cr | ₹21.44 Cr | ₹20.68 Cr | ₹21.11 Cr | ₹18.7 Cr | ₹21.42 Cr |
| Depreciation & Amortisation | ₹78.17 Cr | ₹60.91 Cr | ₹58.59 Cr | ₹58.89 Cr | ₹91.64 Cr | ₹67.61 Cr | ₹62.59 Cr | ₹64.35 Cr | ₹69.1 Cr | ₹58.12 Cr | ₹59.02 Cr | ₹58.11 Cr |
| Other Expenses | ₹747.87 Cr | ₹600.2 Cr | ₹622.63 Cr | ₹575.18 Cr | ₹622.73 Cr | ₹484.64 Cr | ₹627.51 Cr | ₹570.64 Cr | ₹683.1 Cr | ₹513.2 Cr | ₹584.64 Cr | ₹634.05 Cr |
| Total Expenses | ₹2,008.83 Cr | ₹1,878.48 Cr | ₹1,842.69 Cr | ₹1,823.37 Cr | ₹1,856.7 Cr | ₹1,717.61 Cr | ₹2,224.49 Cr | ₹1,965.26 Cr | ₹2,047.63 Cr | ₹2,004.56 Cr | ₹2,057.71 Cr | ₹1,998.95 Cr |
| Profit Before Exceptional Items & Tax | ₹455.3 Cr | ₹744.32 Cr | ₹800.71 Cr | ₹665.38 Cr | ₹299.83 Cr | ₹738.4 Cr | ₹767.67 Cr | ₹640.94 Cr | ₹401.53 Cr | ₹585.69 Cr | ₹638.72 Cr | ₹318.92 Cr |
| Exceptional Items | -₹119.21 Cr | -₹38.17 Cr | ₹0 | ₹14.29 Cr | ₹0 | ₹0 | ₹0 | ₹0 | -₹12.52 Cr | -₹51.31 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹336.09 Cr | ₹706.15 Cr | ₹800.71 Cr | ₹679.67 Cr | ₹299.83 Cr | ₹738.4 Cr | ₹767.67 Cr | ₹640.94 Cr | ₹389.01 Cr | ₹534.38 Cr | ₹638.72 Cr | ₹318.92 Cr |
| Total Tax Expense | ₹119.03 Cr | ₹84.01 Cr | ₹77.05 Cr | ₹57.41 Cr | ₹73.95 Cr | ₹62.17 Cr | ₹70.09 Cr | ₹57.69 Cr | ₹64.04 Cr | ₹30.15 Cr | -₹7.79 Cr | ₹47.48 Cr |
| Net Profit | ₹217.06 Cr | ₹622.14 Cr | ₹786.73 Cr | ₹656.16 Cr | ₹276.94 Cr | ₹723.12 Cr | ₹697.58 Cr | ₹583.25 Cr | ₹324.97 Cr | ₹504.23 Cr | ₹646.51 Cr | ₹271.44 Cr |
| Other Comprehensive Income | ₹18.5 Cr | -₹9.57 Cr | -₹2.16 Cr | -₹2.15 Cr | -₹4.03 Cr | -₹2.49 Cr | -₹2.5 Cr | -₹2.48 Cr | ₹35 Lakh | -₹1.56 Cr | -₹1.57 Cr | -₹1.57 Cr |
| Total Comprehensive Income | ₹235.56 Cr | ₹612.57 Cr | ₹784.57 Cr | ₹654.01 Cr | ₹272.91 Cr | ₹720.63 Cr | ₹695.08 Cr | ₹580.77 Cr | ₹325.32 Cr | ₹502.67 Cr | ₹644.94 Cr | ₹269.87 Cr |
| EBITDA (computed) | ₹549.71 Cr | ₹820.74 Cr | ₹872.05 Cr | ₹737.06 Cr | ₹408.38 Cr | ₹827.01 Cr | ₹847.83 Cr | ₹726.73 Cr | ₹491.31 Cr | ₹664.92 Cr | ₹716.44 Cr | ₹398.45 Cr |
| Basic EPS | ₹18.16 | ₹52.03 | ₹60.53 | ₹52.04 | ₹18.89 | ₹56.56 | ₹58.34 | ₹48.78 | ₹27.18 | ₹42.17 | ₹54.07 | ₹22.70 |
| Diluted EPS | ₹18.16 | ₹52.03 | ₹60.53 | ₹52.04 | ₹18.89 | ₹56.56 | ₹58.34 | ₹48.78 | ₹27.18 | ₹42.17 | ₹54.07 | ₹22.70 |
Shareholding Pattern of Alkem Laboratories Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 51.20%, foreign institutional investors hold 10.16%, domestic institutional investors hold 21.40%, retail and other public shareholders hold 17.25% of Alkem Laboratories Limited. The company had 62,835 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 51.20% | 51.20% | 51.20% | 53.04% | 55.13% | 55.66% |
| Public | 48.80% | 48.80% | 48.80% | 46.96% | 44.87% | 44.34% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 51.20% | 55.13% | 56.74% | 57.16% | 57.13% | 60.16% | 65.88% | 66.02% | 65.86% | 66.97% | 66.78% |
| Public | 48.80% | 44.87% | 43.26% | 42.84% | 42.87% | 39.84% | 34.12% | 33.98% | 34.14% | 33.03% | 33.22% |
| Promoter change (YoY, %pts) | -3.93 | -1.61 | -0.42 | +0.03 | -3.03 | -5.72 | -0.14 | +0.16 | -1.11 | +0.19 | - |
Board & Governance of Alkem Laboratories Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Alkem Laboratories Limited has 12 directors - 6 independent and 6 executive. The board is chaired by Basudeo N. Singh.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Basudeo N. Singh | Executive Director · Chairperson | 1973-08-08 | 1 |
| Sandeep Singh | Executive Director · MD | 2013-08-09 | 1 |
| Mritunjay Kumar Singh | Executive Director | 2008-02-11 | 1 |
| Madhurima Singh | Executive Director | 2021-12-20 | 1 |
| Sarvesh Singh | Executive Director | 2019-11-11 | 1 |
| Srinivas Singh | Executive Director | 2022-09-14 | 1 |
| Narendra Aneja | Non-Executive - Independent Director | 2020-03-16 | 1 |
| Sujjain Talwar | Non-Executive - Independent Director | 2022-08-05 | 3 |
| Rajeev Kher | Non-Executive - Independent Director | 2024-08-09 | 2 |
| Laxmana Ranjal Shenoy | Non-Executive - Independent Director | 2025-07-13 | 1 |
| Neela Bhattacherjee | Non-Executive - Independent Director | 2025-07-13 | 2 |
| Diwakar Gupta | Non-Executive - Independent Director | 2025-07-13 | 3 |
| Committee | Members |
|---|---|
| Audit Committee | Narendra Aneja (Chairperson), Sandeep Singh, Mritunjay Kumar Singh, Laxmana Ranjal Shenoy, Rajeev Kher, Diwakar Gupta |
| Nomination and remuneration committee | Laxmana Ranjal Shenoy (Chairperson), Basudeo N. Singh, Neela Bhattacherjee, Sujjain Talwar |
| Stakeholders Relationship Committee | Sujjain Talwar (Chairperson), Mritunjay Kumar Singh, Madhurima Singh, Srinivas Singh |
| Risk Management Committee | Mritunjay Kumar Singh (Chairperson), Sandeep Singh, Srinivas Singh, Laxmana Ranjal Shenoy, Diwakar Gupta, Neela Bhattacherjee |
| Corporate Social Responsibility Committee | Madhurima Singh (Chairperson), Srinivas Singh, Rajeev Kher, Narendra Aneja, Sarvesh Singh |
Group Structure of Alkem Laboratories Limited
Alkem Laboratories Limited has 5 subsidiary companies. This group structure data is as of FY 2023. The corporate group structure reflects Alkem Laboratories Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Cachet Pharmaceuticals Private Limited | U24230BR1978PTC001328 | - |
| Indchemie Health Specialities Private Limited | U24230MH1986PTC039692 | - |
| Enzene Biosciences Limited | U24232PN2006PLC165610 | - |
| Alkem Foundation | U85100MH2010NPL206161 | - |
| Connect 2 Clinic Private Limited | U93090MH2020PTC339772 | - |
Showing major subsidiaries. Total: 5.
Charges & Borrowings of Alkem Laboratories Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Jul 2024 | Others | ₹100 Cr | Open |
| 26 Feb 2024 | Others | ₹108 Cr | Open |
| 07 Oct 2023 | Bank of India | ₹85 Cr | Open |
| 24 Aug 2023 | Others | ₹80 Cr | Open |
| 27 Mar 2023 | Hdfc Bank Limited | ₹270.32 Cr | Open |
Total charge records: 46 View all charges
Employees and EPFO Compliance at Alkem Laboratories Limited
Alkem Laboratories Limited has a workforce of 18,498 employees as of Nov 19, 2024.
Employee Count & EPFO Data of Alkem Laboratories Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Alkem Laboratories Limited
GSTIN & GST Filing Data of Alkem Laboratories Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Alkem Laboratories Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Alkem Laboratories Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Alkem Laboratories Limited
MSME Payment Delays by Alkem Laboratories Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Alkem Laboratories Limited
Subsidiaries & Group Companies of Alkem Laboratories Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Alkem Laboratories Limited with ownership details.
MCA Filings & Documents of Alkem Laboratories Limited
MCA Filings & Documents of Alkem Laboratories Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Alkem Laboratories Limited
Recent News on Alkem Laboratories Limited
Frequently Asked Questions about Alkem Laboratories Limited
Alkem Laboratories Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 08 August 1973 (53+ years old) and is registered under CIN L00305MH1973PLC174201. Listed on BSE: 539523 and NSE: ALKEM. The company has 18,498 employees.
Alkem Laboratories Limited reported revenue of ₹13,458 Cr for FY 2025 (up 4.00% YoY).
The current directors of Alkem Laboratories Limited are:
The primary industry of Alkem Laboratories Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Alkem Laboratories Limited is listed on both BSE (code: 539523) and NSE (symbol: ALKEM).
Alkem Laboratories Limited can be reached at the registered office: Alkem House Senapati Bapat Marg Lower Parel, Mumbai, Maharashtra, India – 400013, or through the website alkemlabs.com.